Keywords: تراکستین; Nanoparticles; Polycaprolactone; Biodegradable; Polyethylen glycol; Trabectedin; Phlebitis; Vascular toxicity;
مقالات ISI تراکستین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: تراکستین; Pharmacoeconomic; Medical care; Medico economic; Health; Trabectedin; Soft-tissue-sarcoma; Economic; Cost-effectiveness;
Keywords: تراکستین; Recurrent ovarian cancer; Trabectedin;
Keywords: تراکستین; Trabectedin; Translocation-related sarcoma; Soft tissue sarcoma; Crossover; Intra-patient; Retrospective analysis;
Keywords: تراکستین; Sarcoma; Liposarcoma; Myxoid liposarcoma; Pleomorphic liposarcoma; CDK4; MDM2; FUS-CHOP; Trabectedin;
Keywords: تراکستین; Solitary fibrous tumor; Pleura; Surgery; Chemotherapy; Trabectedin;
Keywords: تراکستین; Trabectedin; Sarcoma; Metastasis; Advanced; RetrospectYon
Keywords: تراکستین; Soft tissue sarcoma; Relapse; Trabectedin; Efficacy; Tolerance; Sarcome des tissus mous; Récidive; Trabectedine; Efficacité; Toxicité;
Keywords: تراکستین; Recurrent ovarian cancer; Trabectedin
Keywords: تراکستین; Trabectedin; Recurrent ovarian cancer; Platinum-sensitive; PLD;
Keywords: تراکستین; Trabectedin; Ovarian cancer; Salvage treatment;
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Keywords: تراکستین; BRCA; ovarian cancer; partial platinum sensitive relapse; trabectedin;
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin
Keywords: تراکستین; CI; ConfidenceInterval; CT; ComputedTomography; CTTA; CT-TexturalAnalysis; DCR; Disease Control Rate; DNA; DeoxyribonucleicAcid; FDG-PET; Fludeoxyglucose-Positron Emission Tomography; Fig.; Figure; GIST; Gastrointestinal Stromal Tumor; NGLD; MNeighboring
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial
Keywords: تراکستین; Trabectedin; Lurbinectedin; Breast cancer; BRCA1; BRCA2;
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial
Keywords: تراکستین; Trabectedin; Dacarbazine; Uterine leiomyosarcoma; Phase 3;
Original ResearchPatient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour
Keywords: تراکستین; Sarcoma; Solitary fibrous tumour; Treatment; Metastasis; Chemotherapy; Anthracycline; Doxorubicin; Ifosfamide; Dacarbazine; Trabectedin; Eribulin; Xenograft; Mice model;
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein
Keywords: تراکستین; Lurbinectedin; Trabectedin; Ascites; α1-Acid glycoprotein; Ovarian cancer;
Trabectedin as a chemotherapy option for patients with BRCA deficiency
Keywords: تراکستین; Trabectedin; Yondelis®; BRCA; Mutations; Sarcoma; Breast; Ovarian cancer;
Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis
Keywords: تراکستین; Sarcoma; Trabectedin; Response assessment;
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
Keywords: تراکستین; Soft-tissue sarcoma; Metastatic; Clinical trial; Trabectedin; Doxorubicin; First line chemotherapy;
Liposarcoma mixoide de células redondas de plexo braquial
Keywords: تراکستین; Liposarcoma mixoide; Liposarcoma de células redondas; Plexo braquial; CirugÃa; Trabectedina; Myxoid liposarcoma; Round cell liposarcoma; Brachial plexus; Surgery; Trabectedin;
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial
Keywords: تراکستین; Trabectedin; Nibrin; Ovarian cancer; Molecular marker
Quantification of trabectedin in human plasma: Validation of a high-performance liquid chromatography–mass spectrometry method and its application in a clinical pharmacokinetic study
Keywords: تراکستین; Trabectedin; HPLC–MS/MS; Human plasma; Pharmacokinetics; Liposarcoma
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
Keywords: تراکستین; Sarcomas; Chemotherapy; Translocation; Trabectedin;
Keywords: تراکستین; cost-effectiveness analysis; decision analytic model; ovarian cancer; trabectedin; UK
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
Keywords: تراکستین; Trabectedin; HMGA; Chromatin; Cancer
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
Keywords: تراکستین; Trabectedin; Uterine cancer; Leiomyosarcoma;
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone ★
Keywords: تراکستین; Trabectedin; Yondelis®; Pegylated liposomal doxorubicin; DOXIL®; Relapsed ovarian cancer; Patient-reported outcome
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
Keywords: تراکستین; NSCLC; Lung; Gene signature; Chemotherapy; Response; Trabectedin;
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
Keywords: تراکستین; Trabectedin; Pegylated liposomal doxorubicin; Recurrent ovarian cancer;
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Keywords: تراکستین; Antitumour activity; Chimeric fusion oncoproteins; Chromosomal translocation; Sarcoma; Trabectedin;
Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers
Keywords: تراکستین; Leiomyosarcoma; Uterine neoplasms; Soft tissue sarcoma; Trabectedin; Chemotherapy
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Keywords: تراکستین; Docetaxel; Trabectedin; Ovarian Cancer
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
Keywords: تراکستین; CA-125; Rustin criteria; Platinum; Relapsed ovarian cancer; Trabectedin
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer
Keywords: تراکستین; Relapsed ovarian cancer; Trabectedin; Yondelis®; Pegylated liposomal doxorubicin; DOXIL®
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
Keywords: تراکستین; Sarcoma; DNA repair; Trabectedin; Yondelis; ET-743
Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action
Keywords: تراکستین; Yondelis®; Trabectedin; Fas; Dexamethasone; Caspase 8; Flip (L)
Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
Keywords: تراکستین; ET-743; trabectedin; ESFT; Ewing sarcoma family of tumors; TCR; transcription-coupled nucleotide excision repair; GSEA; gene set enrichment analysis;
New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort
Keywords: تراکستین; Liposarcoma; Targeted therapy; MDM2; Dedifferentiation; Trabectedin; PPARγ; PI3K/AKT
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study
Keywords: تراکستین; Trabectedin; Endometrial cancer; Time to progression; Overall survival; Progression-free survival; YONDELIS, ET-743
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours
Keywords: تراکستین; Phase I; Trabectedin; Cisplatin; Combination; Ovarian cancer; Pharmacokinetics
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
Keywords: تراکستین; Phase I; Trabectedin; Doxorubicin; Combination; Breast cancer; Soft tissue sarcoma
In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping
Keywords: تراکستین; Trabectedin; In vitro metabolism; Human; Monkey; CYP reaction phenotyping
Role of homologous recombination in trabectedin-induced DNA damage
Keywords: تراکستین; Trabectedin; DNA repair; HR and NER
Experience of the Use of Trabectedin (ET-743, Yondelisâ¢) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre
Keywords: تراکستین; Ecteinascidin 743; ET-743; sarcoma; trabectedin; Yondelisâ¢;
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
Keywords: تراکستین; Advanced sarcoma; Trabectedin; Steroid premedication; Toxicity;
Hepatotoxicity and metabolism of trabectedin: a literature review
Keywords: تراکستین; Trabectedin; Metabolism; Hepatotoxicity; Review;